Songuigama Coulibaly1, Jean-Paul D.U. N'Guessan1, Jean-Fabrice K. Koffi 1,2, Soro T. Grâce1 and Mahama Ouattara1*

1Unité pédagogique de Chimie Thérapeutique et Chimie Organique, UFR Sciences Pharmaceutiques et Biologiques, Université FHB, 01 BP V34 Abidjan, Côte d’Ivoire.

2 Université Paris-Saclay, CNRS, BioCIS, Orsay, France.

Corresponding Author E-mail: mahama.dpm@gmail.com

Article Publishing History
Article Received on : 26 Sep 2024
Article Accepted on :
Article Published : 19 Dec 2024

ABSTRACT:

The treatment of tuberculosis (TB) faces several challenges, such as the emergence of drug-resistant TB, long treatment duration, management of latent TB, and toxic adverse effects leading to non-compliance with treatment. To address this, WHO encourages the search for new molecules that are more effective and better tolerated. In this context, hybrid molecules of the 5-nitro heteroaryl-phenylpropenone type have been designed as new anti-tuberculosis drugs. These compounds were developed by molecular hybridization, combining a pentagonal 5-nitro heteroaryl with a phenylpropenone functional chain. Four derivatives were synthesized by condensation of a 5-nitro heteroaryl carbaldehyde derivative and a selected ketone, with yields ranging from 20 to 74%. Their structure was confirmed by spectroscopic methods. These new compounds must now be evaluated on different strains of Mycobacterium tuberculosis to confirm their anti-tuberculosis potential.

KEYWORDS:

Anti-tuberculous; Chalcones; Heteroaryl pentagonals; 5-nitro heteroaryl-phenylpropenone

Download this article as:  Copy the following to cite this article:

Coulibaly S, Guessan J. P. D. U. N, Koffi J. F. K, Grâce S. T. Ouattara M. Synthesis of Some 5-nitro Heteroaryl-phenylpropenones with Antituberculosis. Orient J Chem 2024;40(6).

Copy the following to cite this URL:

Coulibaly S, Guessan J. P. D. U. N, Koffi J. F. K, Grâce S. T. Ouattara M. Synthesis of Some 5-nitro Heteroaryl-phenylpropenones with Antituberculosis. Orient J Chem 2024;40(6). Available from: https://bit.ly/400QBxl

Introduction

Tuberculosis remains one of the deadliest infectious diseases, particularly in regions with limited access to treatment1. Despite progress, challenges such as non-compliance, long treatment duration, adverse effects, latent bacilli management, and multi-drug resistance persist2-4. According to the WHO, drug-resistant bacilli compromise global tuberculosis control efforts, necessitating continued research into new drugs4-6. Nitrated pentagonal heterocycles, especially 5-nitro derivatives, have emerged as promising candidates for tackling resistant strains7-8. Bicyclic 5-nitro derivatives, such as delanamide, show potential for drug-resistant tuberculosis treatment9. These heterocycles, vital in medicinal chemistry, are present in various therapeutic agents10-11. Combining them with nitro groups and chalcone phenylpropenone linkages may yield novel anti-tuberculosis compounds12-13. This study focuses on synthesizing 5-nitro heteroaryl-phenylpropenone hybrids as potential anti-tuberculosis drugs. The Claisen-Schmidt condensation method14, often performed in basic media, is widely used for synthesizing chalcone hybrids due to the stability of enolate intermediates compared to carbocations in acidic conditions. However, basic conditions pose challenges for unstable compounds, such as 5-nitroheteroaryl-derived aldehydes, which are prone to ring opening. Although acidic conditions are less explored due to lower yields, they provide an alternative for such sensitive compounds15-16. Here, we aim to synthesize these hybrids using the acid Claisen-Schmidt method, contributing to the development of innovative anti-tuberculosis drugs.

Materials and Methods

Identification and characterization of all the products

Proton (1H, 300MHz) and carbon (13C, 75 MHz) NMR spectra were recorded on a Brucker avance 300 apparatus at room temperature in appropriate solvents. Spectra were referenced to the solvent in which they were made (1H : CDCl3 = 7.26 ppm) and (13C : CDCl3 = 77.16 ppm). Tetramethylsilane (TMS) is used as reference and chemical shifts are expressed in parts per million (ppm) while coupling constants (J) are expressed in Hertz (Hz). Signal multiplicity is represented by the following abbreviations: s (singlet), d (doublet), m (multiplet or massive). Solvents and reagents were purchased from Sigma Aldrich (France) and used as supplied. The melting points of the compounds were determined on a Köfler bench and are uncorrected.

Design of 5-nitro heteroaryl-phenylpropenones

Tuberculosis remains a major infectious disease worldwide, necessitating innovative strategies to overcome drug resistance. One promising approach involves hybrid molecules combining multiple chemical entities with strong anti-infective potential17, 18. Following this concept, we designed 5-nitro heteroaryl-phenylpropenones by linking pentagonal 5-nitro heteroaryls to the phenylpropenone chain of chalcones. Pentagonal 5-nitro heterocycles are key scaffolds in therapeutic agents such as nitrofuran (nifuratel, nifuroxazide), 5-nitroimidazole (metronidazole, secnidazole), and 5-nitrothiazole derivatives (niridazole, tenonitrozole)19. Notably, metronidazole targets dormant Mycobacterium tuberculosis, a phase resistant to conventional drugs20, 21. Metronidazole analogues, including delamanide, are used against multidrug-resistant tuberculosis (MDR-TB) by inhibiting mycolic acid synthesis, essential for bacterial cell walls22–25. Studies also highlight the antituberculosis potential of nitrated pentagonal heterocycles, such as 5-nitro furan derivatives, which inhibit M. tuberculosis growth and stimulate immune cells like macrophages26–29. Chalcones, phenolic compounds found in plants, exhibit diverse biological activities, including anti-tuberculosis effects30. They act via mechanisms such as inhibiting thiol-functional enzymes, disrupting cell wall synthesis, and modulating immune responses31. Chalcones also impair bacterial biofilm formation, a key virulence factor of M. tuberculosis. Synthetic chalcones have shown activity against M. tuberculosis by compromising cell wall integrity32 and interfering with bacterial enzymes33. Combining the complementary properties of chalcones and 5-nitro heterocycles, we synthesized 5-nitro heteroaryl-phenylpropenones as potential anti-tuberculosis agents targeting multiple aspects of M. tuberculosis biology. This strategy holds promise for developing new therapies to combat drug-resistant tuberculosis.

Synthesis of 5-nitro heteroaryl-phenylpropenones

Basic Claisen-schmidt condensation test

Commercial acetophenone was reacted with 5-nitro-furan-2-carbaldehyde or 5-nitrothiophene-2-carboxaldehyde using a basic condensation method to produce 5-nitro heteroaryl-phenylpropenones (Figure 2). This approach, based on the method described34 by Ouattara Mahama. involves reacting a methyl ketone derivative with 1.2 equivalents of an aromatic aldehyde in a solution of ethanolic sodium hydroxide (7.5 equivalents) at room temperature for 4 to 6 hours. The reaction progress was monitored hourly by thin-layer chromatography (TLC), which showed the disappearance of starting aterials and the formation of at least four new products. However, these products were difficult to identify under our experimental conditions.

In an attempt to limit what appeared to be parasitic reactions, we carried out two further tests, adjusting the number of base (NaOH) equivalents and the reaction time, as summarized in the table I below.

Table I: Conditions of the different condensation tests in basic medium

 

Number of moles of NaOH

Reaction time

Observation

Test 1

7.5 Equivalent

6 hours

Several products

Test 2

5 Equivalent

4 hours

Several products

Test 3

2 Equivalent

4 hours

Several products

 

Attempts to optimize the synthesis method failed to yield the desired 5-nitro heteroaryl-phenylpropenones. This failure could be explained by the instability of 5-nitro-furan-2-carbaldehyde and 5-nitro thiophene-2-carboxaldehyde in basic media. Indeed, these compounds can undergo degradation or transformation reactions, such as hydrolysis or nucleophilic addition reactions. Such reactions can lead to the loss of the nitro function or the formation of ring-opening degradation products35. (Figure 3)

Figure 3: Reaction diagram showing the degradation of 5-nitro-furan-2-carbaldehyde in a basic medium

Click here to View Figure

Claisen-schmidt condensation in acid medium

Given the difficulties of condensation in a basic medium, we opted for condensation in an acidic medium using the method described by Tawari and colleagues36. This involves reacting 5-nitro-furan-2-carbaldehyde or 5-nitrothiophene-2-carboxaldehyde (1a or 1b) with acetophenone or its 4-nitro derivative (2a or 2b) in acetic acid. The reaction is carried out at reflux in the presence of sulfuric acid as catalyst (Figure 4). The 5-nitro heteroaryl-phenylpropenones (3a – 3d) are obtained in yields ranging from 20.66% to 74.31%.

The synthesis of 5-nitro heteroaryl-phenylpropenone derivatives follows this general procedure: In a round-bottom flask, 5-nitrothiophene-2-carboxaldehyde (500 mg, 3.18 mmol) or 5-nitrofuran-2-carboxaldehyde (500 mg, 3.18 mmol) is combined with acetophenone (600 mg, 3.81 mmol) or 4-nitroacetophenone (600 mg, 3.81 mmol) and 0.2 mL of concentrated sulfuric acid in 5 mL of acetic acid. The reaction mixture is heated under reflux for 3–5 hours. After completion, the mixture is cooled to room temperature for 5 hours. The resulting crystals are filtered and washed several times with cold methanol. The product is then dried in an oven at 50°C for 24 hours. The reaction mechanism involves an aldol condensation followed by crotonization in acidic conditions. Initially, the acetophenone carbonyl group is protonated, allowing tautomerization to its enol form. The enol’s double bond acts as a nucleophile, attacking the aldehyde’s carbonyl group to form a β-hydroxyketone. This intermediate then undergoes dehydration, yielding the desired product as shown in Figure 5.

Results and discussion

The different strategies and synthesis methods adopted during our research allowed us to synthesize four derivatives with 5-nitro heteroaryl-phenylpropenone structures for antituberculosis applications. The proton and carbon NMR data of the different synthesized molecules are given below.

(E)-3-(5-nitrofuran-2-yl)-1-phénylprop-2-èn-1-one

Light brown powder, yield :74.31%, mp : 139°C, 1H NMR (300 MHz, CDCl3) : δ 8.07 – 7.98 (m, 2H), 7.90 (d, J = 4.3 Hz, 1H), 7.82 (d, J = 15.5 Hz, 1H), 7.70 – 7.60 (m, 1H), 7.58 – 7.48 (m, 3H), 7.29 (d, J = 4.3 Hz, 1H). 13C NMR (75 MHz, CDCl3) : δ 188.69, 146.27, 137.28, 134.86, 133.52, 129.59, 129.05, 128.87, 128.20, 127.53, 127.1, 124.96, 119.0

(E)-3-(5-nitrofuran-2-yl)-1-(4-nitrophényl)prop-2-èn-1-one

Black brown powder, yield : 72.48%, mp : 220°C, 1H NMR (300 MHz, CDCl3) : δ 8.40 (d, J = 7.6 Hz, 2H), 8.17 (d, J = 8.7 Hz, 2H), 7.88 (d, J = 17.2 Hz, 2H), 7.46 (d, J = 15.2 Hz, 1H), 7.36 (s, 1H). 13C NMR (75 MHz, CDCl3) : δ 186.72, 146.84, 146.82, 133.80, 130.17, 130.13, 128.54, 127.50, 127.62, 126.73, 125.64, 120.55, 119.42

(E)-3-(5-nitrothiophen-2-yl)-1-phénylprop-2-èn-1-one

Golden green powder, yield : 42.58%, mp : 175°C, 1H NMR (300 MHz, CDCl3): δ 8.11 – 8.04 (m, 2H), 7.78 (d, J = 15.5 Hz, 1H), 7.68 – 7.61 (m, 1H), 7.59 – 7.51 (m, 3H), 7.39 (d, J = 3.8 Hz, 1H), 6.86 (d, J = 3.8 Hz, 1H).13C NMR (75 MHz, CDCl3) : δ 187.1, 144.20, 133.6, 130.86, 130.1, 128.6, 128,2, 127.0, 125.10, 121.38, 118.70

(E)-3-(5-nitrofuran-2-yl)-1-(4-nitrophenyl)prop-2-en-1-one

Yellow powder, yield : 20.66 %, mp : 265°C, 1H NMR (300 MHz, CDCl3) : δ 8.44 – 8.35 (m, 2H), 8.26 – 8.18 (m, 2H), 7.80 – 7.58 (m, 2H), 7.41 (d, J = 3.8 Hz, 1H), 6.93 (d, J = 3.8 Hz, 1H). 13C NMR (75 MHz, CDCl3) : δ 189.1, 146.20, 146.6, 131.91, 130.7, 128.1, 127,80, 126.90, 124.6, 122.0, 120.1

The chemical structures of all 5-nitro heteroaryl-phenylpropenones were confirmed using proton and carbon NMR (Nuclear Magnetic Resonance) spectroscopy. Proton NMR (¹H NMR) analysis revealed consistent features across the compounds, with numerous signals in the aromatic region between 6 ppm and 10 ppm. Notably, the ¹H NMR spectra showed the disappearance of the methyl group (CH₃) signal from acetophenone at δ = 2.61 ppm. Instead, two doublets corresponding to ethylenic protons appeared, along with an enrichment of signals in the aromatic region. The ethylenic protons were detected at approximately δ = 7.88 ppm (Hb) and δ = 7.46 ppm (Ha), with a coupling constant of 15 Hz (Figure 6). However, due to conjugation, these protons resonate in weaker fields and overlap with the aromatic signals, making their precise identification challenging. This phenomenon was similarly observed by Etchié Degny in his study of chalcones from quinoxaline and pyrimidine series37. The coupling constant of 15 Hz confirms that the 5-nitro heteroaryl-phenylpropenone derivatives adopt a trans (E) configuration38.

Furthermore, in carbon NMR spectroscopy, in addition to the signals from the aromatic and ethylenic carbons, we observe on the spectra of all the compounds and at approximately the same chemical shift, a signal around 188 ppm that we can attribute to the carbon of the carbonyl group deblinded by mesomeric conjugation with the ethylenic double bond.

Conclusion

This study focuses on the search for new anti-tuberculosis molecules. The goal is to develop more effective compounds that can overcome the drug resistance observed with many current anti-tuberculosis treatments. Using the pharmacochemical approach of molecular hybridization, we designed new compounds with a 5-nitro heteroaryl-phenylpropenone structure. The synthesis involved the condensation of acetophenone derivatives with 5-nitroheterocyclic carbaldehydes in an acidic medium using the Claisen-Schmidt method. Four 5-nitro heteroaryl-phenylpropenone derivatives were successfully synthesized, isolated, and purified, with yields ranging from 20% to 73%. The structures of these compounds were confirmed through standard spectroscopic techniques, including ¹H and ¹³C NMR. These new derivatives, combining the anti-infective properties of the 5-nitroheteroaryl pharmacophore with the phenylpropenone activity modulator of chalcones, are promising candidates for anti-tuberculosis evaluation and may exhibit strong therapeutic potential.

Acknowledgement

The authors would like to thank the BioCIS laboratory of the Université Paris-Saclay for the analysis of the NMR spectra.

Conflict of Interest

The author(s) do not have any conflict of interest.

Funding Sources

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Vanino, E., Granozzi, B., Akkerman, O. W., Munoz-Torrico, M., Palmieri, F., Seaworth, B., Tiberi, S., & Tadolini, M. Update of drug-resistant tuberculosis treatment guidelines: A turning point. International journal of infectious diseases., 2023,130 Suppl 1:S12-S15.
CrossRefBagcchi, S. WHO’s Global Tuberculosis Report 2022. Lancet Microbe., 2023, 4(1):e20.
CrossRef Salina, E. G., & Makarov, V. Mycobacterium tuberculosis Dormancy: How to Fight a Hidden Danger. Microorganisms., 2022, 10(12), 2334.
CrossRef Mancuso, G., Midiri, A., De Gaetano, S., Ponzo, E., & Biondo, C. Tackling Drug-Resistant Tuberculosis: New Challenges from the Old Pathogen Mycobacterium tuberculosis. Microorganisms., 2023, 11(9), 2277.
CrossRef Dirlikov, E., Raviglione, M., & Scano, F. Global Tuberculosis Control: Toward the 2015 Targets and Beyond. Annals of internal medicine., 2015, 163(1), 52–58.
CrossRef Guo, T., Xin, H., & Gao, L. Interpretation of WHO consolidated guidelines on tuberculosis: Module 1: prevention: tuberculosis preventive treatment. Chinese Journal of Antituberculosis., 2023, 45(8), 723.Sriram, D., Yogeeswari, P., Dhakla, P., Senthilkumar, P., Banerjee, D., & Manjashetty, T. H. 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. Bioorganic & Medicinal Chemistry Letters., 2009, 19(4), 1152-1154.
CrossRef Scarim, C. B., & Pavan, F. R. Recent advancement in drug development of nitro (NO2)‐heterocyclic compounds as lead scaffolds for the treatment of Mycobacterium tuberculosis. Drug Development Research., 2022, 83(4), 842-858.
CrossRef Upton, A. M., Cho, S., Yang, T. J., Kim, Y., Wang, Y., Lu, Y., & Franzblau, S. G. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy., 2015 , 59(1), 136-144.
CrossRef Günay, N. S., Çapan, G., Ulusoy, N., Ergenç, N., Ötük, G., & Kaya, D. 5-Nitroimidazole derivatives as possible antibacterial and antifungal agents. Il Farmaco., 1999, 54(11-12), 826-831.
CrossRef Amit, A., Rawat, D. S., & Rawat, M. S. M. 5-Nitroimidazole derivatives: A scope of Modification for Medicinal chemists. Research Journal of Chemical Sciences., 2013, 104-113.Rice, A. M., Long, Y., & King, S. B. Nitroaromatic Antibiotics as Nitrogen Oxide Sources. Biomolecules., 2021, 11(2), 267
CrossRef haliwal, J. S., Moshawih, S., Goh, K. W., Loy, M. J., Hossain, M. S., Hermansyah, A., Kotra, V., Kifli, N., Goh, H. P., Dhaliwal, S. K. S., Yassin, H., & Ming, L. C. Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives. Molecules (Basel, Switzerland)., 2022, 27(20), 7062.
CrossRef Winter, C., Caetano, J. N., Araújo, A. B. C., Chaves, A. R., Ostroski, I. C., Vaz, B. G., & Alonso, C. G. Activated carbons for chalcone production: Claisen-Schmidt condensation reaction. Chemical Engineering Journal., 2016, 303, 604-610.
CrossRef Fine, S. A., & Pulaski, P. D. Reexamination of the Claisen-Schmidt condensation of phenylacetone with aromatic aldehydes. The Journal of Organic Chemistry., 1973, 38(9), 1747-1749.
CrossRef Schmidt, J. G. Ueber die Einwirkung von Aceton auf Furfurol und auf Bittermandelöl bei Gegenwart von Alkalilauge. Berichte der deutschen chemischen Gesellschaft., 1881, 14(1), 1459-1461.
CrossRef Stelitano, G., Sammartino, J. C., & Chiarelli, L. R. Multitargeting compounds: a promising strategy to overcome multi-drug resistant tuberculosis. Molecules., 2020, 25(5), 1239.
CrossRef Srivastava, G., Tiwari, A., & Sharma, A. Computational methods for multi-target drug designing against mycobacterium tuberculosis. Multi-Target Drug Design Using Chem-Bioinformatic Approaches., 2019, 459-483.
CrossRef Elston, D. Systemic antiparasitic agents. Comprehensive dermatologic drug therapy., 2012, 3, 135-41.
CrossRef Wayne, L. G., & Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy., 1994, 38(9), 2054-2058.
CrossRef Carroll, M. W., Jeon, D., Mountz, J. M., Lee, J. D., Jeong, Y. J., Zia, N., … & Cho, S. N. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrobial agents and chemotherapy., 2013, 57(8), 3903-3909.
CrossRef Zhang, J., Ba, Y., Wang, S., Yang, H., Hou, X., & Xu, Z. Nitroimidazole-containing compounds and their antibacterial and antitubercular activities. European journal of medicinal chemistry., 2019, 179, 376-388.
CrossRef Showalter, H. D. Recent progress in the discovery and development of 2-nitroimidazooxazines and 6-nitroimidazooxazoles to treat tuberculosis and neglected tropical diseases. Molecules., 2020, 25(18), 4137.
CrossRef Khoshnood, S., Taki, E., Sadeghifard, N., Kaviar, V. H., Haddadi, M. H., Farshadzadeh, Z., & Heidary, M. Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant Mycobacterium tuberculosis. Frontiers in microbiology., 2021, 12, 717045.
CrossRef Nasiri, M. J., Zangiabadian, M., Arabpour, E., Amini, S., Khalili, F., Centis, R., & Sotgiu, G. Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. International Journal of Infectious Diseases., 2022, 124, S90-S103.
CrossRef Kalinin, S., Vedekhina, T., Paramonova, P., & Krasavin, M. Antimicrobial activity of 5-membered nitroheteroaromatic compounds beyond nitrofurans and nitroimidazoles: Recent progress. Current Medicinal Chemistry., 2021, 28(29), 5926-5982.
CrossRef Elsaman, T., Mohamed, M. S., & Mohamed, M. A. Current development of 5-nitrofuran-2-yl derivatives as antitubercular agents. Bioorganic Chemistry., 2019, 88, 102969.
CrossRef Agre, N., Tawari, N., Maitra, A., Gupta, A., Munshi, T., Degani, M., & Bhakta, S. 3-(5-Nitrofuran-2-yl) prop-2-en-1-one Derivatives, with Potent Antituberculosis Activity, Inhibit A Novel Therapeutic Target, Arylamine N-acetyltransferase, in Mycobacteria. Antibiotics., 2020, 9(7), 368.
CrossRef Turukarabettu, V., Kalluraya, B., & Sharma, M. Design and synthesis of sulfur cross-linked 1, 3, 4-oxadiazole-nitro (furan/thiophene)-propenones as dual inhibitors of inflammation and tuberculosis: molecular docking and Hirshfeld surface analysis. Monatshefte für Chemie-Chemical Monthly., 2019, 150, 1999-2010.
CrossRef Noviany, N., Osman, H., Mohamad, S., Hadi, S., Satria, H., & Buhani, B. Synthesis of some chalcones derivatives series and their antituberculosis activity. Pure and Applied Chemistry., 2024, 96(3), 351-368.
CrossRef Rodríguez-Silva, C. N., Prokopczyk, I. M., & Dos Santos, J. L. The medicinal chemistry of chalcones as anti-Mycobacterium tuberculosis agents. Mini Reviews in Medicinal Chemistry., 2022, 22(16), 2068-2080.
CrossRef Anagani, B., Singh, J., Bassin, J. P., Besra, G. S., Benham, C., Reddy, T. R. K., & Goyal, M. Identification and validation of the mode of action of the chalcone anti-mycobacterial compounds. The Cell Surface., 2020, 6, 100041.
CrossRef Chiaradia, L. D., Mascarello, A., Purificação, M., Vernal, J., Cordeiro, M. N. S., Zenteno, M. E., & Terenzi, H. Synthetic chalcones as efficient inhibitors of Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorganic & medicinal chemistry letters., 2008, 18(23), 6227-6230.
CrossRef Ouattara, M., Sissouma, D., Koné, M. W., & Yavo, W. Compounds with imidazopyridinyl-arylpropenone structure, potential new anti-infective agents. Comptes Rendus. Chimie., 2016, 19(7), 850-856.
CrossRef Cisak, A., Rzeszowska-Modzelewska, K., & Brzezińska, E. Reactivity of 5-nitro-2-furaldehyde in alkaline and acidic solutions. Acta Poloniae Pharmaceutica., 2001, 58(6), 427-434.Tawari, N. R., Bairwa, R., Ray, M. K., Rajan, M. G. R., & Degani, M. S. Design, synthesis, and biological evaluation of 4-(5-nitrofuran-2-yl) prop-2-en-1-one derivatives as potent antitubercular agents. Bioorganic & medicinal chemistry letters., 2010, 20(21), 6175-6178.
CrossRef Beguemsi, T., N’guessan, R. B., Degny, E., Voglozin, A., & N’guessan, Y. T. Etude theorique et experimentale de la cyclocondensation dienes-chalcones. Journal de la Société ouest-africaine de chimie, 2004, (18), 49-65.Lesot, P. The art of discriminating between enantiomers. Plein Sud, Journal de l’Université de Paris-Sud (XI)., 2002, 51, 18-19.

This work is licensed under a Creative Commons Attribution 4.0 International License.

About The Author

Related Posts